Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary) ; Secukinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms BE RADIANT
  • Sponsors UCB Biopharma; UCB Pharma Inc

    • Most Recent Events

    • 15 Nov 2023 Results comparing the efficacy of bimekizumab (BKZ) vs secukinumab (SEC) through 48 weeks (wks) for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis who had moderate to severe nail involvement at baseline, presented at the ACR Convergence 2023
    • 15 Nov 2023 Results (n=654) assessing the efficacy of BKZ, as measured by complete or near complete skin clearance using the Psoriasis Area and Severity Index (PASI), over 144 weeks, and assess long-term safety of BKZ treatment presented at the ACR Convergence 2023
    • 09 Oct 2023 According to an UCB media release, data from this study will be presented as oral presentation at at the 32nd European Academy of Dermatology and Venereology (EADV) Congress, October 11-14th in Berlin, Germany.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top